Merck, known as MSD outside of the United States and Canada, received U.S. Food and Drug Administration (FDA) approval for Keytruda (pembrolizumab).  This is Merck’s anti-PD-1 therapy, for the treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with ...